← Leaderboards
Denise C Connolly
Fox Chase Cancer Center
$4,562,794
Attributed
$6,492,532
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $900.4K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,492,532 · 6
By mechanism
R01$4,489,463 · 2
P30$896,729 · 2
U54$800,078 · 1
S10$306,262 · 1
Top collaborators
- Mansoor M. Amiji5 shared
- Timothy P Coleman5 shared
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Joanne F Dorgan$8,245,231
- Gregory P Adams$4,024,285
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsLinkTissue MicroarrayPathologyTissuesResearch PersonnelNormal Tissue MorphologySpecimenClinical DataMolecularBasic ScienceBiological MarkersFox Chase Cancer CenterParticipantUniversitiesCell Culture TechniquesDiagnosticSamplingBiological ModelsInformed ConsentCollaborationsResourcesDoctor Of PhilosophyEthics
Grant awards (24)
Pilot Research Project: Evaluating Breast Cancer Patient Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling$269,040
U54 · FY2025 · CA · contact PI
Biosample Repository Facility$42,511
P30 · FY2025 · CA · contact PI
Pilot Research Project: Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling$188,112
U54 · FY2024 · CA · contact PI
Pilot Research Project: Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling$342,926
U54 · FY2023 · CA · contact PI
Shared Resource: Biosample Repository Facility$49,200
P30 · FY2021 · CA · contact PI
Shared Resource: Biosample Repository Facility$170,419
P30 · FY2020 · CA · contact PI
Shared Resource: Biosample Repository Facility$8,696
P30 · FY2020 · CA · contact PI
Shared Resource: Biosample Repository Facility$159,442
P30 · FY2019 · CA · contact PI
Shared Resource: Biosample Repository Facility$152,041
P30 · FY2018 · CA · contact PI
Shared Resource: Biosample Repository Facility$10,869
P30 · FY2018 · CA · contact PI
Shared Resource: Biosample Repository Facility$5,968
P30 · FY2018 · CA · contact PI
Shared Resource: Biosample Repository Facility$152,036
P30 · FY2017 · CA · contact PI
STARlet easyBlood$306,262
S10 · FY2016 · OD · contact PI
Shared Resource: Biosample Repository Facility$145,547
P30 · FY2016 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$523,530
R01 · FY2015 · CA
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$665,610
R01 · FY2014 · CA
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$596,489
R01 · FY2013 · CA
The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis$303,948
R01 · FY2013 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$540,181
R01 · FY2012 · CA
The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis$323,047
R01 · FY2012 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$568,797
R01 · FY2011 · CA
The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis$316,103
R01 · FY2011 · CA · contact PI
The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis$325,879
R01 · FY2010 · CA · contact PI
The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis$325,879
R01 · FY2009 · CA · contact PI